# Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device

> **NCT03450863** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 320 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1 Diabetes

## Interventions

- **DRUG:** Fast-acting insulin aspart

## Key facts

- **NCT ID:** NCT03450863
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-22
- **Primary completion:** 2019-09-04
- **Final completion:** 2019-09-04
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03450863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03450863, "Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03450863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*